GlassScriptPhysician profile
Stephen Kuperberg
NPI 1346477296
$9,645.48
in general payments reported to CMS, 2019-2025
17 companies · $4,521 in 2025
The $4,521 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,160 · 2020: $241 · 2021: $482 · 2023: $530 · 2024: $1,711 · 2025: $4,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,898 · Travel and Lodging: $1,652 · Food and Beverage: $1,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,897.50 |
| Travel and Lodging | $1,652.06 |
| Food and Beverage | $1,212.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $4,025.19 | 2019-2025 | Keytruda |
| Intuitive Surgical, INC. | $2,102.15 | 2023-2024 | Da Vinci Surgical System |
| Pulmonx Corporation | $1,318.69 | 2019 | |
| Kestra Medical Technology Services, INC. | $412.32 | 2025 | Assure Wcd |
| Mallinckrodt Hospital Products INC. | $365.54 | 2020-2021 | |
| Galvanize Therapeutics, INC | $350.38 | 2023-2025 | Aliya System |
| Ethicon INC. | $282.90 | 2021 | |
| Genentech USA, INC. | $266.26 | 2019 | |
| Mallinckrodt Enterprises LLC | $218.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.54 | 2019 | |
| Boston Scientific Corporation | $42.19 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $32.09 | 2021 | |
| Astellas Pharma US INC | $21.28 | 2019 | |
| Inari Medical, INC. | $15.51 | 2019 | |
| Glaxosmithkline, LLC. | $12.40 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $12.00 | 2019 | |
| Bard Access Systems, INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Kuperberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.